Email ID
Sign me in automatically next time
Creabilis' TrkA kinase inhibitor shows promise in clinic for psoriasis

The clinical-stage European biotechnology company Creabilis says it hopes to complete Phase IIb studies of its topical TrkA kinase inhibitor, CT327, for psoriasis by the end of the third quarter of...
10 March 2011
Pial Ganguli

Please Login to read the full article.
04 April 2016
Stockholm, Sweden
06 April 2016
Hamburg, Germany
JOB OF THE WEEK Promote your job vacancy
© 2016 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36